Section 1: A Personal Battle with a Silent Disease
My maternal grandmother fell — and she never truly got back up.What began as a fall became the beginning of the end of her independence, her mobility, and eventually her life.
Today, my mother is 87 years old. She walks with a cane. Every step she takes reminds me that osteoporosis is not an abstract medical condition. It is a family story. It is a women’s health story. It is a longevity story. And for many families, it is a story that begins silently decades before the fracture.
I have two younger sisters. I have a daughter. And now, as I enter my own later stage of life, I sometimes ask myself a question that is both personal and scientific: Is this our family history — or is this a risk we can finally learn to monitor before it becomes irreversible?
Section 2: The Limitation of the "Snapshot" Approach
As a nanobiosensor scientist, I have spent much of my career thinking about how invisible biological signals can be measured, digitized, and turned into actionable information. Osteoporosis is one of the clearest examples of why this matters.DXA, or bone density scanning, remains essential. It is the clinical standard for measuring bone mineral density, and U.S. guidelines recommend osteoporosis screening for women aged 65 and older, and for younger postmenopausal women who are at increased risk. But DXA is often performed only every one or two years. It shows bone structure at a point in time. It does not directly show the current biological activity of bone remodeling.
Section 3: Decoding the Biological Activity of Bone
Bone, however, is alive. It is constantly being broken down and rebuilt. That biological activity can be partly measured through bone turnover markers such as P1NP and β-CTX-I. In 2025, an international consensus from IOF, ESCEO, and IFCC reaffirmed serum P1NP and plasma β-CTX-I as reference bone turnover markers in osteoporosis, particularly for monitoring treatment effectiveness and adherence.This is why I believe the future of osteoporosis care must move beyond a single snapshot. We need longitudinal monitoring. We need earlier biological feedback. We need to understand not only whether bone density is already low, but whether a person is becoming more vulnerable to fracture over time.
Image created with AI to symbolize the generational connection in bone health.
It is a family question.
My grandmother’s fall is the past.
My mother’s cane is the present.
My daughter’s future is the reason I believe we must build something better.
In my next article, I will explain why DXA remains essential — but why bone turnover markers such as P1NP and β-CTX may become increasingly important for monitoring osteoporosis before fractures happen.
Author Bio:
Dr. HeaYeon Lee is a nanobiosensor scientist and CEO of MARA Nanotech, dedicated to digitizing bone health.)
Note: Some conceptual images in this article were generated using AI to represent family narratives.
Section 4: Building a Better Future for the Next Generation
For me, this is not only a scientific question.It is a family question.
My grandmother’s fall is the past.
My mother’s cane is the present.
My daughter’s future is the reason I believe we must build something better.
In my next article, I will explain why DXA remains essential — but why bone turnover markers such as P1NP and β-CTX may become increasingly important for monitoring osteoporosis before fractures happen.
Author Bio:
Dr. HeaYeon Lee is a nanobiosensor scientist and CEO of MARA Nanotech, dedicated to digitizing bone health.)
Note: Some conceptual images in this article were generated using AI to represent family narratives.
MARA Global Insight
"MARA Nanotech’s Global Health Reports are being updated sequentially on our official English blog (health.maranano.com). Be the first to explore the integration of global medical trends and cutting-edge nanotechnology."
[Visit MARA Official Site: https://www.maranano.com/]
